Leigh Hsu
Corporate Officer/Principal at CARSGEN THERAPEUTICS HOLDINGS LIMITED
Profile
Leigh Hsu is a professional who currently holds the position of Senior Vice President-Business Development at CARsgen Therapeutics Holdings Ltd.
He has previously worked as Director-Business Development at ACADIA Pharmaceuticals, Inc. and as Vice President-Corporate Development & Strategy at Lpath, Inc. Dr. Hsu holds an MBA degree from the University of California, Irvine and a doctorate degree from the University of California San Diego.
Leigh Hsu active positions
| Companies | Position | Start |
|---|---|---|
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | Corporate Officer/Principal | 31/05/2017 |
Former positions of Leigh Hsu
| Companies | Position | End |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
Lpath, Inc.
 Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Training of Leigh Hsu
| University of California San Diego | Doctorate Degree |
| University of California, Irvine | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | Health Technology |
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| Private companies | 1 |
|---|---|
Lpath, Inc.
Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Leigh Hsu
